EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
Cash payment of £1.425m as a settlement for the total deferred cash consideration due in relation to DiaSpect Medical AB.
EKF Diagnostics Holdings plc provides a trading update for the year ended 31 December 2014.
EKF announces that Ron Zwanziger, a former Chief Executive of Alere, has bought 3% of the Company.
EKF Diagnostics Holdings plc was informed on 1 October 2014 that David Evans, Executive Chairman, purchased shares in the Company on 1 October 2014.
EKF Diagnostics announces that it has entered into a two year research collaboration with Massachusetts General Hospital (MGH) to develop PointMan assays that can effectively detect treatable cancer mutations in blood samples.
EKF Diagnostics announces its unaudited interim results for the six months ended 30 June 2014.
EKF announce the appointment of David Toohey and Doris-Ann Williams MBE to the Board as Non-Executive Directors.
EKF Diagnostics the AIM listed point-of-care, central laboratory and molecular diagnostics business, provides the following trading update for the six months ended 30 June 2014.
EKF Diagnostics Holdings plc, announces the appointment of Dr Tito Bacarese-Hamilton to the Board of Directors of the Company, as Chief Technology Officer with immediate effect.
Update to shareholders on reimbursement levels received by recently acquired Selah Genomics, Inc.